Copyright
©The Author(s) 2018.
World J Gastroenterol. Jan 14, 2018; 24(2): 266-273
Published online Jan 14, 2018. doi: 10.3748/wjg.v24.i2.266
Published online Jan 14, 2018. doi: 10.3748/wjg.v24.i2.266
Table 1 Univariate prognostic analysis of clinicopathological features n (%)
Variable | AFPAGC(n = 105) | Median OS (mo) | P value |
Sex | |||
Male | 82 (78.1) | 15.0 | 0.144 |
Female | 23 (21.9) | 11.3 | |
Age (yr) | |||
≥ 60 | 49 (46.7) | 15.0 | 0.189 |
< 60 | 56 (53.3) | 12.0 | |
Serum AFP level (ng/mL) | |||
≥ 500 | 37 (35.2) | 13.0 | 0.806 |
< 500 | 68 (64.5) | 14.6 | |
Primary lesion site | |||
EGJ | 41 (39.8) | 15.0 | 0.245 |
Non-EGJ | 62 (60.2) | 12.0 | |
Differentiation degree | |||
Well | 30 (29.4) | 15.4 | 0.496 |
Poor | 66 (64.7) | 12.9 | |
HAS | 6 (5.9) | 4.5 | |
Lauren classification | |||
Intestinal | 45 (57.0) | 15.4 | 0.352 |
Non-intestinal | 34 (43.0) | 14.6 | |
HER2 status | |||
Positive | 20 (24.4) | 17.5 | 0.583 |
Negative | 62 (75.6) | 14.6 | |
LM | |||
Present | 63 (60.0) | 12.0 | 0.048a |
Absent | 42 (40.0) | 16.7 | |
Peritoneal metastasis | |||
Present | 16 (15.4) | 6.17 | 0.001a |
Absent | 88 (84.6) | 15.2 | |
Non-regional LNM | |||
Present | 56 (53.3) | 11.0 | 0.042a |
Absent | 49 (46.7) | 17.9 | |
Other hematogenous metastasis | |||
Present | 27 (25.7) | 10.5 | 0.004a |
Absent | 78 (74.3) | 17.5 | |
PVTT | |||
Present | 13 (12.4) | 8.3 | 0.011a |
Absent | 92 (87.6) | 15.0 | |
First-line regimen | |||
Doublet regimen | 89 (88.1) | 14.6 | 0.850 |
Triplet regimen | 12 (11.9) | 15.1 | |
Evaluation | |||
PR | 42 (48.3) | 17.6 | 0.007a |
SD + PD | 45 (51.7) | 11.1 | |
AFP decline degree | |||
≥ 50% | 49 (55.7) | 17.5 | 0.003a |
< 50% | 39 (44.3) | 10.0 | |
Local treatment for LM | |||
Yes | 19 (18.1) | 17.9 | 0.215 |
No | 86 (81.9) | 12.9 |
Table 2 Comparison of objective response rates to different chemotherapy regimens n (%)
Regimen | Platinum-based doublet regimen(n = 58) | Taxane-based doublet regimen(n = 17) | Triplet regimen(n =11) | P value |
Overall population | 0.201 | |||
PR | 31 (53.4) | 5 (29.4) | 6 (54.5) | |
SD + PD | 27 (46.6) | 12 (76.4) | 5 (45.5) | |
AFP ≥ 160 ng/mL | 0.067 | |||
PR | 10 (32.3) | 0 (0.0) | 4 (57.1) | |
SD + PD | 21 (67.7) | 7 (100.0) | 3 (42.9) | |
AFP < 160 ng/mL | 0.193 | |||
PR | 21 (77.8) | 5 (50.0) | 2 (50.0) | |
SD + PD | 6 (22.2) | 5 (50.0) | 2 (50.0) |
Table 3 Severe adverse events of different chemotherapy regimens n (%)
Regimen | Platinum-based doublet regimen(n = 72) | Taxane-based doublet regimen(n = 17) | Triplet regimen(n =12) | P value |
≥ G3 AEs | 11 (15.3) | 4 (23.5) | 7 (58.3) | 0.004 |
Table 4 Comparison of response, liver metastasis rate, and overall survival between alpha-fetoprotein ≥ 160 ng/mL and alpha-fetoprotein < 160 ng/mL groups n (%)
Variable | AFP ≥ 160 ng/mL | AFP < 160 ng/mL | P value |
Overall ORR | |||
PR | 14 (30.4) | 28 (68.3) | < 0.001a |
SD + PD | 32 (69.6) | 13 (31.7) | |
ORR to doublet regimens | |||
PR | 10 (26.3) | 26 (70.3) | < 0.001a |
SD + PD | 28 (73.7) | 11 (30.7) | |
ORR to triplet regimens | |||
PR | 4 (57.1) | 2 (50.0) | 0.652 |
SD + PD | 3 (42.9) | 2 (50.0) | |
Liver metastasis rate | 69.8% | 50.0% | 0.030a |
Median OS | 13.0 mo | 14.8 mo | 0.712 |
Table 5 Correlation between decline degree of serum alpha-fetoprotein and response n (%)
Variable | AFP decline ≥ 50% | AFP decline < 50% | P value |
Response | |||
PR | 34 (72.3) | 5 (14.7) | <0.001 |
SD + PD | 13 (27.7) | 29 (85.3) |
Table 6 Multiple Cox regression analysis of prognostic factors
Factor | HR | 95%CI | P value |
LM (present) | 2.809 | 1.363-5.788 | 0.005a |
PM (present) | 4.243 | 2.026-8.883 | < 0.001a |
Non-regional LNM (present) | 3.743 | 1.928-7.268 | < 0.001a |
Other hematogenous metastasis (present) | 1.479 | 0.692-3.161 | 0.312 |
PVTT (present) | 2.341 | 1.030-5.320 | 0.048a |
Response (SD + PD) | 1.92 | 0.953-3.867 | 0.068 |
AFP decline degree (< 50%) | 1.876 | 0.980-3.589 | 0.057 |
- Citation: Wang YK, Shen L, Jiao X, Zhang XT. Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP. World J Gastroenterol 2018; 24(2): 266-273
- URL: https://www.wjgnet.com/1007-9327/full/v24/i2/266.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i2.266